



January 7, 2020
Luxna Biotech Co., Ltd.

Notice: Adoption of The 4th Cyclic Innovation for Clinical Empowerment(CiCLE) by Japan Agency for Medical Research and Development(AMED)

Please be informed that Luxna Biotech Co., Ltd. (Osaka, President and CEO Hideaki Sato) applied for “The 4th Cyclic Innovation for Clinical Empowerment (CiCLE, Start-up type; ViCLE) which was publicly sought by Japan Agency for Medical Research and Development (hereinafter referred to as AMED). Then our theme “Development of Antisense Therapy of Spinal Cord Injury” was adopted. This theme is based on the research theme “Drug Discovery of Spinal Cord Injury with a Neural Regeneration Promoting Effect” by Professor Kosei Takeuchi from Aichi Medical University of Medical which was supported by the iD3 Booster of the Division of Strategic Planning and Evaluation, AMED. We aim to apply the therapeutics agent to a clinic.

Contact information

Management Division, Luxna Biotech Co., Ltd.

E-mail: info@luxnabiotech.co.jp

HP: <https://luxnabiotech.co.jp/en/>